TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10333196

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg o.d. plus azithromycin 500 mg o.d. and tinidazole 500 mg b.i.d. (LAT)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg o.d. plus azithromycin 500 mg o.d. and tinidazole 500 mg b.i.d. (PAT)
Number of subjects: 70
Study: 7723896

Group type: EXPERIMENTAL
Intervention: Zn sulfate (100 mg/day p.o.)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Diiodohydroxyquinolein (DQ) (80 mg/day p.o.)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Zn sulfate plus DQ (100 mg/day Zn sulfate and 80 mg/day DQ p.o.)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 2257740

Group type: EXPERIMENTAL
Intervention: Multi-size Mahua Ring
Number of subjects: 800

Group type: COMPARATOR
Intervention: One-size Mahua Ring
Number of subjects: 800
Study: 366146

Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 0
Study: 31198144

Group type: EXPERIMENTAL
Intervention: Protocol 1 (55 mL iodinated contrast media)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Protocol 2 (60 mL iodinated contrast media)
Number of subjects: 92
Study: 26917198

Group type: EXPERIMENTAL
Intervention: Ascorbic acid supplementation (2g 24h and 2h before surgery, 1g twice a day for five days after surgery)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group (no ascorbic acid supplementation)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Ascorbic acid supplementation
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 105
Study: 26501105

Group type: EXPERIMENTAL
Intervention: Pravastatin 10 mg/day
Number of subjects: 1578

Group type: COMPARATOR
Intervention: Control (no statins)
Number of subjects: 1578
Study: 23922179

Group type: EXPERIMENTAL
Intervention: Alcohol (0.8 g/kg for men, 0.75 g/kg for women)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control
Number of subjects: 15
Study: 21288119

Group type: EXPERIMENTAL
Intervention: Medication management (optional treatment module for ADHD)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Psychosocial interventions
Number of subjects: 96
Study: 19675535

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 29
Study: 16915363

Group type: EXPERIMENTAL
Intervention: Cryoablation
Number of subjects: 81

Group type: COMPARATOR
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 81
Study: 15615000

Group type: EXPERIMENTAL
Intervention: PST-based language model for text generation from Taiwanese Sign Language
Number of subjects: 10
Study: 10604344

Group type: EXPERIMENTAL
Intervention: Biofeedback enhanced pelvic floor exercises
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no biofeedback)
Number of subjects: 30
Study: 9054843

Group type: COMPARATOR
Intervention: Aspirin alone (ASA)
Number of subjects: 801

Group type: EXPERIMENTAL
Intervention: Combined ticlopidine and aspirin (TIC-ASA)
Number of subjects: 801
Study: 7683702

Group type: COMPARATOR
Intervention: risperidone (2 mg/day)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: risperidone (6 mg/day)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: risperidone (6-16 mg/day)
Number of subjects: 135

Group type: COMPARATOR
Intervention: haloperidol (20 mg/day)
Number of subjects: 135

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 135

Group type: COMPARATOR
Intervention: risperidone (2, 6, and 16 mg/day)
Number of subjects: 135
Study: 3727918

Group type: EXPERIMENTAL
Intervention: Tolfenamic acid 300 mg/day
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Propranolol 120 mg/day
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 29803590

Group type: EXPERIMENTAL
Intervention: Renal denervation with the Paradise system (ReCor Medical, Palo Alto, CA, USA)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Sham procedure (renal angiography only)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Comparison between renal denervation and sham procedure
Number of subjects: 146

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 146
Study: 27082709

Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 25028657

Group type: EXPERIMENTAL
Intervention: Spectral-domain optical coherence tomography (OCT)
Number of subjects: 338

Group type: COMPARATOR
Intervention: Standard automated perimetry (SAP)
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Peripapillary retinal nerve fiber layer (RNFL) thickness measured with Cirrus OCT
Number of subjects: 338

Group type: COMPARATOR
Intervention: Healthy group
Number of subjects: 338
Study: 21750964

Group type: EXPERIMENTAL
Intervention: AT→CMF
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AT→CMX
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AC→TX
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Capecitabine (X) in AT→CMX
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall response rates (ORR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Breast-conserving surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 0
Study: 20936190

Group type: EXPERIMENTAL
Intervention: Functional training of facial mimic muscles
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group (no functional training)
Number of subjects: 92
Study: 18094668

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 32

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 32
Study: 16205449

Group type: EXPERIMENTAL
Intervention: Pravastatin (20-40 mg daily)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study: 12434282

Group type: EXPERIMENTAL
Intervention: Anastrozole 1 mg
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Anastrozole 10 mg
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Anastrozole (1 and 10 mg)
Number of subjects: 26
Study: 10507380

Group type: COMPARATOR
Intervention: Phenytoin (1-week course)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Valproate (1-month course)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Valproate (6-month course)
Number of subjects: 132
Study: 8921100

Group type: EXPERIMENTAL
Intervention: Vaginal progesterone alone (P group)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Combination of vaginal progesterone and human chorionic gonadotrophin (P/HCG group)
Number of subjects: 176
Study: 1669237

Group type: EXPERIMENTAL
Intervention: Class I antiarrhythmics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 6981163

Group type: EXPERIMENTAL
Intervention: Low-dose trimethoprim (TMP)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMZ)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Nitrofurantoin macrocrystals
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 31676642

Group type: EXPERIMENTAL
Intervention: 10-week interactive, family-based lifestyle intervention followed by four maintenance sessions
Number of subjects: 186

Group type: COMPARATOR
Intervention: Modified programme with the same 10-week sessions in the family portal and four group sessions
Number of subjects: 186
Study: 28819067

Group type: EXPERIMENTAL
Intervention: TARGIT-IORT
Number of subjects: 0

Group type: COMPARATOR
Intervention: EBRT
Number of subjects: 0
Study: 27259315

Group type: EXPERIMENTAL
Intervention: Levobupivacaine (0.75%) with 5 μg mL(‐1) of adrenaline, injected at T 8‐9 interspace, dosage: 1.8 mg kg(‐1), duration: 1.5 min
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Levobupivacaine (0.75%) in patients with liver dysfunction
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (normal liver function)
Number of subjects: 20
Study: 23880403

Group type: EXPERIMENTAL
Intervention: Accelerated weightbearing (AR) protocol
Number of subjects: 28

Group type: COMPARATOR
Intervention: Current best practice (CR) weightbearing regimen
Number of subjects: 28
Study: 21825934

Group type: EXPERIMENTAL
Intervention: Prophylactic inferior vena cava filter (pIVCF) placement
Number of subjects: 38

Group type: COMPARATOR
Intervention: No pIVCF
Number of subjects: 38
Study: 19857635

Group type: EXPERIMENTAL
Intervention: Prescriptive lifestyle advice
Number of subjects: 203

Group type: COMPARATOR
Intervention: General lifestyle advice
Number of subjects: 203
Study: 16207382

Group type: EXPERIMENTAL
Intervention: DGIP (Dutch EASYcare Study Geriatric Intervention Programme)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Regular care
Number of subjects: 151
Study: 12870723

Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no corticosteroids)
Number of subjects: 20
Study: 10478769

Group type: EXPERIMENTAL
Intervention: Spinal manipulation
Number of subjects: 77

Group type: COMPARATOR
Intervention: Needle acupuncture
Number of subjects: 77

Group type: COMPARATOR
Intervention: Nonsteroidal anti-inflammatory medication (tenoxicam with ranitidine)
Number of subjects: 77
Study: 9592305

Group type: EXPERIMENTAL
Intervention: cimetidine 800 mg at bedtime + teprenone 50 mg thrice daily
Number of subjects: 106

Group type: COMPARATOR
Intervention: cimetidine 800 mg at bedtime alone
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: cimetidine + teprenone
Number of subjects: 106

Group type: COMPARATOR
Intervention: cimetidine alone
Number of subjects: 106
Study: 1888587

Group type: EXPERIMENTAL
Intervention: 0.1% hexetidine mouthwash
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo mouthwash
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 40
Study: 6631327

Group type: EXPERIMENTAL
Intervention: Performance-contingent reward condition (tutors promised a toy if the first-grader learned all problems)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Noncontingent reward condition (tutors promised a toy for teaching)
Number of subjects: 96

Group type: COMPARATOR
Intervention: No reward condition (tutors taught without promise of a toy)
Number of subjects: 96
Study: 30817591

Group type: EXPERIMENTAL
Intervention: bupivacaine + 5 μg Dex
Number of subjects: 90

Group type: COMPARATOR
Intervention: bupivacaine + saline (Control)
Number of subjects: 90
Study: 28049525

Group type: EXPERIMENTAL
Intervention: Nutrition therapy and high intensity interval training
Number of subjects: 116

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 116
Study: 27553436

Group type: EXPERIMENTAL
Intervention: Decision tree model for predicting outcomes based on head AIS severity, Marshall CT score, and pupillary reactivity.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison to two previously published and validated models.
Number of subjects: 0
Study: 24597755

Group type: EXPERIMENTAL
Intervention: Paliperidone ER
Number of subjects: 4051

Group type: COMPARATOR
Intervention: All other oral antipsychotics
Number of subjects: 4051
Study: 23439942

Group type: EXPERIMENTAL
Intervention: Topical application of natural honey
Number of subjects: 60

Group type: COMPARATOR
Intervention: Topical application of 0.15% benzydamine hydrochloride
Number of subjects: 60

Group type: COMPARATOR
Intervention: Topical application of 0.9% normal saline
Number of subjects: 60
Study: 19047319

Group type: EXPERIMENTAL
Intervention: Heliox
Number of subjects: 11

Group type: COMPARATOR
Intervention: Room air
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Heliox at isotime
Number of subjects: 11

Group type: COMPARATOR
Intervention: Room air at isotime
Number of subjects: 11
Study: 17174572

Group type: EXPERIMENTAL
Intervention: Manual delineation of hippocampal atrophy rates
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Regional fluid registration (forward) of hippocampal atrophy rates
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Regional fluid registration (backward) of hippocampal atrophy rates
Number of subjects: 18
Study: 16372792

Group type: EXPERIMENTAL
Intervention: Aceclofenac 100 mg twice daily
Number of subjects: 100

Group type: COMPARATOR
Intervention: Etoricoxib 60 mg twice daily
Number of subjects: 100
Study: 11961179

Group type: EXPERIMENTAL
Intervention: meloxicam 7.5 mg bid
Number of subjects: 10

Group type: COMPARATOR
Intervention: naproxen 500 mg bid
Number of subjects: 10
Study: 9584497

Group type: EXPERIMENTAL
Intervention: Calcium supplementation of 1000 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7619973

Group type: EXPERIMENTAL
Intervention: metaCPP
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control
Number of subjects: 18
Study: 2137322

Group type: EXPERIMENTAL
Intervention: Oral ketoconazole therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable (unaffected controls)
Number of subjects: 0
Study: 861118

Group type: EXPERIMENTAL
Intervention: Thiopentone 3 mg/kg
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Ketamine 2 mg/kg
Number of subjects: 77
Study: 31748505

Group type: EXPERIMENTAL
Intervention: 600 mg CBDV
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 28430718

Group type: EXPERIMENTAL
Intervention: Trauma Collaborative Care (TCC) program
Number of subjects: 95
Study: 25351456

Group type: EXPERIMENTAL
Intervention: anamorelin HCl
Number of subjects: 477

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 477
Study: 24029559

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Health education (Healthy Topics - HT)
Number of subjects: 41
Study: 21729832

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 1002

Group type: COMPARATOR
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 1002
Study: 18722479

Group type: EXPERIMENTAL
Intervention: Color Cue Single task (CCS)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Color Cue Dual task (CCD)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No Cue (NC)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Size Cue (SC)
Number of subjects: 40
Study: 17002630

Group type: EXPERIMENTAL
Intervention: Prototype PRISM Chagas assay
Number of subjects: 8288
Study: 11890955

Group type: EXPERIMENTAL
Intervention: Orosensory stimulation with lipid and carbohydrate stimuli (butter, UFA margarine, jelly)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Orosensory stimulation with cracker and butter
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (no oral stimulation)
Number of subjects: 16
Study: 9527732

Group type: EXPERIMENTAL
Intervention: Midazolam (M)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Propofol (P)
Number of subjects: 40
Study: 7885818

Group type: EXPERIMENTAL
Intervention: Iconic cues (pure tones with frequency identical to the signal)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Complex cues (complex tones with a missing fundamental equal to the signal)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Relative cues (pure tones with a certain frequency relation to the signal)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-cue condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Complex-cue condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Iconic and relative cues
Number of subjects: 0
Study: 2381005

Group type: EXPERIMENTAL
Intervention: Percutaneous (Seldinger wire) technique
Number of subjects: 327

Group type: COMPARATOR
Intervention: Open peritoneal lavage technique
Number of subjects: 327
Study: 364763

Group type: EXPERIMENTAL
Intervention: Clofibrate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ICI 55,897
Number of subjects: 0
Study: 29723512

Group type: EXPERIMENTAL
Intervention: Remimazolam
Number of subjects: 461

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 461
Study: 26829012

Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cabazitaxel with G-CSF
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cabazitaxel without G-CSF
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low NLR and grade ≥3 neutropenia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High NLR and no grade ≥3 neutropenia
Number of subjects: 0
Study: 24251969

Group type: EXPERIMENTAL
Intervention: Intravenous iron (1000 mg single administration)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Oral iron (200 mg daily for 3 months)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study: 24007976

Group type: COMPARATOR
Intervention: Bare-metal stents
Number of subjects: 11557

Group type: COMPARATOR
Intervention: Early-generation DES
Number of subjects: 11557

Group type: COMPARATOR
Intervention: Newer-generation DES
Number of subjects: 11557
Study: 20074724

Group type: EXPERIMENTAL
Intervention: Uterine fibroid embolization
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study: 18838524

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (omega-3 fatty acids)
Number of subjects: 3
Study: 16191850

Group type: EXPERIMENTAL
Intervention: Short contact dithranol treatment
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: UVB phototherapy
Number of subjects: 250

Group type: COMPARATOR
Intervention: Inpatient dithranol treatment
Number of subjects: 250
Study: 12577228

Group type: EXPERIMENTAL
Intervention: Gemcitabine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cisplatin and gemcitabine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gemcitabine combined with bolus or infusional 5‐fluorouracil, capecitabine, metalloproteinase inhibitors, or FTI tipifarnib
Number of subjects: 0
Study: 9578187

Group type: EXPERIMENTAL
Intervention: MKS492 40 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: MKS492 20 mg
Number of subjects: 18
Study: 7713834

Group type: EXPERIMENTAL
Intervention: Strength training
Number of subjects: 76

Group type: COMPARATOR
Intervention: Endurance training
Number of subjects: 76
Study: 2547540

Group type: EXPERIMENTAL
Intervention: Intra-articular injection of Hyalgan (HA, Na-hyaluronate, 20 mg/2 ml)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 16
Study: 13501

Group type: EXPERIMENTAL
Intervention: Fenoterol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hexoprenaline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ritodrine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All drugs
Number of subjects: 0
Study: 30541365

Group type: EXPERIMENTAL
Intervention: Ramadan fasting
Number of subjects: 44
Study: 28342775

Group type: EXPERIMENTAL
Intervention: Cash and Counseling (treatment group)
Number of subjects: 456

Group type: COMPARATOR
Intervention: Agency-based care (control group)
Number of subjects: 456
Study: 26040586

Group type: EXPERIMENTAL
Intervention: Alprazolam 0.25 mg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Alprazolam 0.5 mg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Alprazolam 1 mg
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 22762200

Group type: EXPERIMENTAL
Intervention: Short time (overnight) smoking abstinence
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Nicotine patch (21 mg) after overnight smoking abstinence
Number of subjects: 45

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 45
Study: 21070216

Group type: EXPERIMENTAL
Intervention: Good seizure control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Absence of depression and fewer adverse treatment effects at 4 years
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fair/poor health perception, presence of depression, reduced sense of mastery, and more adverse treatment effects at follow-up
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Psychosocial interventions to increase self-mastery, reduce health concerns, treat depression, and promote positive adjustment
Number of subjects: 0
Study: 19756816

Group type: EXPERIMENTAL
Intervention: Septal pacing with dynamic atrial overdrive (DAO) and AV delay optimization
Number of subjects: 25

Group type: COMPARATOR
Intervention: Conventional pacing with dynamic atrial overdrive (DAO) and AV delay optimization
Number of subjects: 25
Study: 17570430

Group type: EXPERIMENTAL
Intervention: Early treatment group (aspirin treatment initiation 24 hours after discontinuing bladder irrigation)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Late treatment group (aspirin treatment initiation 3 weeks after surgery)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 120
Study: 14967093

Group type: EXPERIMENTAL
Intervention: Systematic review or RCT (level I)
Number of subjects: 980

Group type: EXPERIMENTAL
Intervention: Non-experimental or consensus evidence (level II)
Number of subjects: 980

Group type: EXPERIMENTAL
Intervention: No good evidence (level III)
Number of subjects: 980

Group type: EXPERIMENTAL
Intervention: Unique diagnosis-treatment pairs analysis
Number of subjects: 980
Study: 11285108

Group type: EXPERIMENTAL
Intervention: Interactive computer use with weekly nurse training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weekly training with a significant other
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interactive computer use alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no computer terminal use)
Number of subjects: 0
Study: 9602225

Group type: EXPERIMENTAL
Intervention: cetirizine 10 mg o.d.
Number of subjects: 27

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 27
Study: 8066906

Group type: EXPERIMENTAL
Intervention: Antismoking advice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-help manuals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Measurements of smoking dependent chemical factors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multifactorial methods
Number of subjects: 0
Study: 30452609

Group type: EXPERIMENTAL
Intervention: Fractional flow reserve (FFR)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: resting instantaneous wave‐free ratio (iFR)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: resting Pd/Pa
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: FFR ≤0.80
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: iFR ≤0.89
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Pd/Pa ≤0.92
Number of subjects: 129